Q32 Bio announced positive topline results from the 36-week Part B of its SIGNAL-AA Phase 2a clinical trial for bempikibart, a drug targeting severe alopecia areata. The trial showed meaningful hair regrowth and a good safety profile. The company plans to start a registration-directed Phase 3 program in the first half of 2027, pending regulatory discussions. With $106.3 million cash plus $200 million raised in July 2026, Q32 Bio is financially positioned to advance its development program and explore broader applications of bempikibart and a related antibody, ADX-914-XL.
Two directors of Equitable Holdings sold shares recently, with Bertram L. Scott selling 2,780 shares and Craig C. MacKay selling 2,000 shares. Meanwhile, institutional investors showed mixed activity: Engineers Gate Manager LP drastically cut its hol...
Shares of Greenland-linked mining companies surged following a new U.S.-Denmark-Greenland security agreement that boosted investor interest in Greenland's mineral resources. Greenland Mines Ltd. jumped over 229%, while Critical Metals Corp. rose near...
Biotech stocks and leveraged ETFs were the biggest losers in the market, with Cue Biopharma dropping 23.7% despite positive Phase 2 clinical results. Leveraged ETFs tied to AMD, Strategy, and Novo Nordisk also saw sharp declines due to their daily-re...
Priority Technology Holdings is being taken private in a $1.6 billion deal led by its Chairman and CEO, Thomas Priore. The acquisition price is $8.05 per share, matching the analyst price target set by Lake Street, which downgraded the stock to 'Hold...
General Mills is set to report its Q3 2026 earnings with an expected 16.3% decline in earnings per share to $0.72 and revenue forecast around $4.35 billion, down from last year. Despite these declines, the company reaffirmed its full-year adjusted EP...
